Keybank National Association OH Has $3.37 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Keybank National Association OH lessened its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 31.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,692 shares of the biotechnology company's stock after selling 21,892 shares during the period. Keybank National Association OH's holdings in BioMarin Pharmaceutical were worth $3,371,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Proficio Capital Partners LLC bought a new position in BioMarin Pharmaceutical in the fourth quarter worth about $920,000. Smartleaf Asset Management LLC raised its position in shares of BioMarin Pharmaceutical by 111.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 885 shares of the biotechnology company's stock worth $58,000 after buying an additional 466 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in BioMarin Pharmaceutical during the fourth quarter worth approximately $36,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 1.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,423,508 shares of the biotechnology company's stock valued at $93,567,000 after buying an additional 21,880 shares during the period. Finally, Assetmark Inc. boosted its position in shares of BioMarin Pharmaceutical by 1,391.9% during the 4th quarter. Assetmark Inc. now owns 4,953 shares of the biotechnology company's stock valued at $326,000 after purchasing an additional 4,621 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company's stock.

Insider Buying and Selling at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,786 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $59.31, for a total value of $105,927.66. Following the sale, the chief accounting officer owned 14,173 shares of the company's stock, valued at $840,600.63. This trade represents a 11.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.85% of the company's stock.

BioMarin Pharmaceutical Stock Performance

BMRN stock traded up $0.92 during midday trading on Tuesday, hitting $58.33. 1,224,050 shares of the company traded hands, compared to its average volume of 1,736,167. BioMarin Pharmaceutical Inc. has a twelve month low of $52.93 and a twelve month high of $94.85. The stock has a market capitalization of $11.19 billion, a price-to-earnings ratio of 21.68, a price-to-earnings-growth ratio of 0.79 and a beta of 0.17. The company has a quick ratio of 3.49, a current ratio of 5.52 and a debt-to-equity ratio of 0.10. The business has a 50 day simple moving average of $57.77 and a 200-day simple moving average of $62.83.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Morgan Stanley began coverage on BioMarin Pharmaceutical in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $97.00 price target for the company. Wall Street Zen raised BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. Citigroup dropped their target price on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Finally, The Goldman Sachs Group reduced their price target on shares of BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating for the company in a research report on Monday, May 5th. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $93.61.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.